Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | F13A1 | P00488 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10592850 | 0.90 | KDM4E (0.84) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3203944 | 0.89 | KDM4E (0.70) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6845394 | 0.89 | KDM4E (0.70) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3523937 | 0.87 | KDM4E (0.68) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6706700 | 0.87 | HSD17B10 (0.56) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4864495 | 0.85 | KDM4E (0.66) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14966449 | 0.84 | SMN1; SMN2 (0.68) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10451965 | 0.84 | KDM4E (0.64) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16017577 | 0.84 | PLK1 (0.64) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4867311 | 0.84 | ALDH1A1 (0.73) | KDM4EF13A1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| CN-1469876-A | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists | �Ʒ� | 2004-01-21 | — | — | CN | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-4278680-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER MANNHEIM GMBH (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4207341-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER-MANNHEIM GMBH (DE) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | KDM4E 3213/4885F13A1 1607/4885SMN1; SMN2 2178/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | KDM4E 3070/4885F13A1 1338/4885SMN1; SMN2 2100/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | KDM4E 3754/4885F13A1 1414/4885SMN1; SMN2 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.